Arcutis Biotherapeutics Stock Performance

ARQT Stock  USD 13.81  0.98  7.64%   
Arcutis Biotherapeutics has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.3, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Arcutis Biotherapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Arcutis Biotherapeutics is expected to be smaller as well. Arcutis Biotherapeutics right now shows a risk of 4.86%. Please confirm Arcutis Biotherapeutics value at risk, and the relationship between the standard deviation and kurtosis , to decide if Arcutis Biotherapeutics will be following its price patterns.

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Arcutis Biotherapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Arcutis Biotherapeutics may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more

Actual Historical Performance (%)

One Day Return
(6.28)
Five Day Return
(3.10)
Year To Date Return
(11.88)
Ten Year Return
(41.15)
All Time Return
(41.15)
JavaScript chart by amCharts 3.21.151234567891011Dec2025Feb 01020304050
JavaScript chart by amCharts 3.21.15Arcutis Biotherapeutics Arcutis Biotherapeutics Dividend Benchmark Dow Jones Industrial
1
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
12/06/2024
2
Disposition of 1691 shares by Burnett Patrick of Arcutis Biotherapeutics at 14.0 subject to Rule 16b-3
12/31/2024
3
Disposition of 12500 shares by Matthew Moore of Arcutis Biotherapeutics at 28.72 subject to Rule 16b-3
01/30/2025
4
Disposition of 2173 shares by Edwards Larry Todd of Arcutis Biotherapeutics at 12.7 subject to Rule 16b-3
02/03/2025
5
Insider Sell Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc
02/05/2025
6
Suvretta Capital Management, LLC Reduces Holdings in Kura Oncology Inc
02/14/2025
7
Arcutis Biotherapeutics Inc to Participate in TD Cowen 45th Annual Health Care Conference
02/19/2025
8
Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE Cream 0.05 percent in Children 2 to 5 Years Old with Mild to Moderate...
02/24/2025
9
Arcutis Biotherapeutics Inc Q4 2024 Earnings EPS Loss of 0. ...
02/25/2025
10
Mizuho Raises Arcutis Biotherapeutics Price Target to 21.00
02/26/2025
11
Arcutis Biotherapeutics, Inc. Just Reported Yearly Earnings Have Analysts Changed Their Mind On The Stock
02/28/2025
Begin Period Cash Flow89.3 M
  

Arcutis Biotherapeutics Relative Risk vs. Return Landscape

If you would invest  1,261  in Arcutis Biotherapeutics on December 4, 2024 and sell it today you would earn a total of  22.00  from holding Arcutis Biotherapeutics or generate 1.74% return on investment over 90 days. Arcutis Biotherapeutics is currently generating 0.144% in daily expected returns and assumes 4.8623% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Arcutis, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
JavaScript chart by amCharts 3.21.15CashMarketARQT 012345 -0.050.000.050.100.15
       Risk  
Given the investment horizon of 90 days Arcutis Biotherapeutics is expected to generate 6.29 times more return on investment than the market. However, the company is 6.29 times more volatile than its market benchmark. It trades about 0.03 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly -0.09 per unit of risk.

Arcutis Biotherapeutics Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Arcutis Biotherapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Arcutis Biotherapeutics, and traders can use it to determine the average amount a Arcutis Biotherapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0296

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskARQTHuge Risk
Negative Returns

Estimated Market Risk

 4.86
  actual daily
43
57% of assets are more volatile

Expected Return

 0.14
  actual daily
2
98% of assets have higher returns

Risk-Adjusted Return

 0.03
  actual daily
2
98% of assets perform better
Based on monthly moving average Arcutis Biotherapeutics is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Arcutis Biotherapeutics by adding it to a well-diversified portfolio.

Arcutis Biotherapeutics Fundamentals Growth

Arcutis Stock prices reflect investors' perceptions of the future prospects and financial health of Arcutis Biotherapeutics, and Arcutis Biotherapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Arcutis Stock performance.
Return On Equity-1.14
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-400%-300%-200%-100%
Return On Asset-0.23
Profit Margin(0.71) %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Operating Margin(0.11) %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Current Valuation1.51 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%
Shares Outstanding118.64 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31100%200%300%400%500%600%
Price To Book10.31 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Price To Sales7.74 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%
Revenue196.54 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Gross Profit177.41 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80,000%-60,000%-40,000%-20,000%0%
EBITDA(109.62 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-311,000%2,000%3,000%4,000%5,000%6,000%7,000%
Net Income(140.04 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-311,000%2,000%3,000%4,000%5,000%6,000%
Cash And Equivalents282.17 M
Cash Per Share5.47 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312,000%4,000%6,000%8,000%
Total Debt3.38 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3110,000%20,000%30,000%40,000%50,000%60,000%
Debt To Equity0.40 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-1,400%-1,200%-1,000%-800%-600%-400%-200%
Current Ratio10.75 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%50%100%150%200%250%
Book Value Per Share1.34 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-5,000%-4,000%-3,000%-2,000%-1,000%0%1,000%
Cash Flow From Operations(112.16 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-311,000%2,000%3,000%4,000%5,000%6,000%
Earnings Per Share(1.16) X
Market Capitalization1.52 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%
Total Asset348.89 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312,000%4,000%6,000%8,000%10,000%12,000%
Retained Earnings(1.12 B)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-315,000%10,000%15,000%20,000%
Working Capital254.81 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Current Asset87.18 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312,000%4,000%6,000%8,000%10,000%12,000%
Current Liabilities4.42 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312,000%4,000%6,000%8,000%10,000%12,000%

About Arcutis Biotherapeutics Performance

Assessing Arcutis Biotherapeutics' fundamental ratios provides investors with valuable insights into Arcutis Biotherapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Arcutis Biotherapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 277.18  263.33 
Return On Tangible Assets(0.41)(0.43)
Return On Capital Employed(0.48)(0.50)
Return On Assets(0.40)(0.42)
Return On Equity(0.89)(0.93)

Things to note about Arcutis Biotherapeutics performance evaluation

Checking the ongoing alerts about Arcutis Biotherapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Arcutis Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Arcutis Biotherapeutics had very high historical volatility over the last 90 days
The company reported the previous year's revenue of 196.54 M. Net Loss for the year was (140.04 M) with profit before overhead, payroll, taxes, and interest of 177.41 M.
Arcutis Biotherapeutics currently holds about 282.17 M in cash with (112.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.47.
Arcutis Biotherapeutics has a frail financial position based on the latest SEC disclosures
Over 98.0% of the company shares are held by institutions such as insurance companies
Latest headline from finance.yahoo.com: Arcutis Biotherapeutics, Inc. Just Reported Yearly Earnings Have Analysts Changed Their Mind On The Stock
Evaluating Arcutis Biotherapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Arcutis Biotherapeutics' stock performance include:
  • Analyzing Arcutis Biotherapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Arcutis Biotherapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining Arcutis Biotherapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Arcutis Biotherapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Arcutis Biotherapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Arcutis Biotherapeutics' stock. These opinions can provide insight into Arcutis Biotherapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Arcutis Biotherapeutics' stock performance is not an exact science, and many factors can impact Arcutis Biotherapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Arcutis Stock Analysis

When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.